Skip to main content

Table 2 Univariate analysis of prognostic factors for overall survival (OS) and progression-free survival (PFS) of patients with DLBCL

From: Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study

Variable

5-year OS rate (%)

P value

5-year PFS rate (%)

P value

Age (years)

 

< 0.01

 

0.02

 ≤ 60

66.7

 

54.7

 

 > 60

42.1

 

38.8

 

Clinical stage

 

< 0.01

 

< 0.01

 I–II

68.2

 

61.7

 

 III–IV

50.7

 

38.4

 

B symptoms

 

0.02

 

< 0.01

 No

63.8

 

54.2

 

 Yes

48.7

 

38.7

 

Spleen involvement

 

0.01

 

< 0.01

 No

62.4

 

53.0

 

 Yes

41.8

 

31.4

 

IPI

 

< 0.01

 

< 0.01

 < 3

64.4

 

55.6

 

 ≥ 3

41.9

 

29.6

 

LDH (U/L)

 

< 0.01

 

< 0.01

 ≤ 245

72.7

 

60.1

 

 > 245

46.2

 

39.0

 

β2-MG (mg/L)

 

< 0.01

 

0.07

 ≤ 2.52

73.2

 

54.6

 

 > 2.52

42.2

 

35.7

 

Rituximab

 

0.04

 

0.20

 Without

53.1

 

46.4

 

 With

71.9

 

58.4

 

First-line chemotherapy CR

 

< 0.01

 

0.04

 No

49.1

 

45.9

 

 Yes

72.2

 

57.2

 

PD-L1 expression in tumor cells

 

0.02

 

0.01

 Negative

67.3

 

59.6

 

 Positive

50.0

 

39.6

 

PD-L1 expression in tumor microenvironment

 

0.21

 

0.26

 Negative

62.0

 

52.5

 

 Positive

48.9

 

39.3

 
  1. IPI international prognostic index, LDH lactate dehydrogenase, β2-MG β2-microglobulin, CR complete remission, PD-L1 programmed cell death-ligand 1